JP2018534304A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534304A5
JP2018534304A5 JP2018524713A JP2018524713A JP2018534304A5 JP 2018534304 A5 JP2018534304 A5 JP 2018534304A5 JP 2018524713 A JP2018524713 A JP 2018524713A JP 2018524713 A JP2018524713 A JP 2018524713A JP 2018534304 A5 JP2018534304 A5 JP 2018534304A5
Authority
JP
Japan
Prior art keywords
adjuvant
composition
poly
lipid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018524713A
Other languages
English (en)
Japanese (ja)
Other versions
JP6989134B2 (ja
JP2018534304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2016/051324 external-priority patent/WO2017083963A1/en
Publication of JP2018534304A publication Critical patent/JP2018534304A/ja
Publication of JP2018534304A5 publication Critical patent/JP2018534304A5/ja
Priority to JP2021128886A priority Critical patent/JP2021181462A/ja
Application granted granted Critical
Publication of JP6989134B2 publication Critical patent/JP6989134B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018524713A 2015-11-18 2016-11-15 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 Expired - Fee Related JP6989134B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021128886A JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562256875P 2015-11-18 2015-11-18
US62/256,875 2015-11-18
PCT/CA2016/051324 WO2017083963A1 (en) 2015-11-18 2016-11-15 Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128886A Division JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Publications (3)

Publication Number Publication Date
JP2018534304A JP2018534304A (ja) 2018-11-22
JP2018534304A5 true JP2018534304A5 (OSRAM) 2019-10-31
JP6989134B2 JP6989134B2 (ja) 2022-01-05

Family

ID=58717143

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018524713A Expired - Fee Related JP6989134B2 (ja) 2015-11-18 2016-11-15 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
JP2021128886A Pending JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021128886A Pending JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Country Status (7)

Country Link
US (2) US11160861B2 (OSRAM)
EP (1) EP3377099A4 (OSRAM)
JP (2) JP6989134B2 (OSRAM)
CN (1) CN108430505A (OSRAM)
AU (1) AU2016355926A1 (OSRAM)
CA (1) CA3005127C (OSRAM)
WO (1) WO2017083963A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. リピドa模倣体、調製方法、及びその使用
WO2017083963A1 (en) * 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
AU2018250226B2 (en) 2017-04-04 2025-04-24 Barinthus Biotherapeutics North America, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
AU2017423053A1 (en) * 2017-07-10 2020-01-23 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
KR102098097B1 (ko) * 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
AU2017438994A1 (en) * 2017-11-09 2020-05-28 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
US11666644B2 (en) 2018-09-04 2023-06-06 Treos Bio Limited Peptide vaccines
KR102292147B1 (ko) * 2020-11-18 2021-08-23 주식회사 차백신연구소 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트
JP2024506381A (ja) * 2021-02-16 2024-02-13 ヴァクシテック ノース アメリカ, インコーポレイテッド 両親媒性ペプチドに基づく自己集合ナノ粒子
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
JPWO2023145755A1 (OSRAM) 2022-01-25 2023-08-03
WO2024092352A1 (en) * 2022-11-04 2024-05-10 Immunovaccine Technologies Inc. Compositions that recruit and activate antigen presenting cells
AU2023390365A1 (en) * 2022-12-08 2025-07-03 Thomas Jefferson University Immune adjuvants for polysaccharide vaccines
WO2024186623A1 (en) * 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) * 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
CA2203843C (en) 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
AU2002214861B2 (en) 2000-11-07 2006-09-28 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1853305B1 (en) 2005-02-04 2014-08-20 Survac ApS Survivin peptide vaccine
CN101151020B (zh) 2005-02-07 2011-09-07 利波特卡有限公司 佐剂材料
US20100129385A1 (en) 2005-02-08 2010-05-27 Jackson David C Immunogenic molecules
JP5106384B2 (ja) 2005-04-27 2012-12-26 ライデン ユニバーシティ メディカル センター Hpv誘導性上皮内腫瘍の治療方法及び治療手段
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
AU2008269721B2 (en) 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
WO2008147187A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
AU2008303023B2 (en) 2007-09-27 2014-01-09 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
JP5591705B2 (ja) * 2007-10-03 2014-09-17 イムノバクシーン・テクノロジーズ・インコーポレイテッド 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
ATE545411T1 (de) 2008-03-25 2012-03-15 Formac Pharmaceuticals N V Herstellungsverfahren für feststoffdispersionen
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
WO2010123365A1 (en) 2009-04-24 2010-10-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Increasing the immunogenicity of epithelial cells infected with human papilloma virus (hpv)
GB201019240D0 (en) 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
US10022441B2 (en) * 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
WO2017083963A1 (en) * 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant

Similar Documents

Publication Publication Date Title
JP2018534304A5 (OSRAM)
Diaz-Arévalo et al. Nanoparticle-based vaccines: opportunities and limitations
Petkar et al. An overview of nanocarrier-based adjuvants for vaccine delivery
Tan et al. Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants
US11077184B2 (en) Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response
Wang et al. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
Woodrow et al. Mucosal vaccine design and delivery
Kaurav et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage
Xu et al. Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives
Huang et al. Research progress on emulsion vaccine adjuvants
JP2014528955A5 (OSRAM)
Liu et al. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice
Korsholm et al. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
Carneiro et al. Protective effect of antigen delivery using monoolein-based liposomes in experimental hematogenously disseminated candidiasis
Soni et al. The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems
US20200054571A1 (en) Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles
Bo et al. Materials‐based vaccines for infectious diseases
Ontiveros-Padilla et al. Development of a broadly active influenza intranasal vaccine adjuvanted with self-assembled particles composed of mastoparan-7 and CpG
Temchura et al. Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand
Gandhapudi et al. Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice., 2023, 15, 432
Barik et al. Nanotechnology-Based Vaccination for TB
Noureddine et al. Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials
Caetano et al. Chitosan-alginate microparticulate delivery system for an alternative route of administration of BCG vaccine
Balar et al. Antigen Selection and Design